Up next

Autoplay

Octreotide Long-Acting Release Therapy in Polycystic Liver Disease

0 Views • 08/25/25
Share
Side Effects
Side Effects
Subscribers
0

Dr. Marie Hogan, an Associate Professor from the Division of Nephrology and Mayo Medical School in Rochester, MN, shares her article appearing in the August 2015 issue of Mayo Clinic Proceedings, regarding results of long-term (~four years) off-label use of the somatostatin analog Octreotide LAR for polycystic liver disease (given as a monthly injection) that demonstrated sustained responses while patients received the drug, and decline in quality of life and increase in liver size when the drug was stopped. Available at: http://tinyurl.com/pubczp5

Show more
0 Comments sort Sort By

Up next

Autoplay